Spectral Cubiq
Autonomous whole slide imaging system with inline quality assurance
Company profile
Company profile
Pramana is a digital pathology company that has developed what it calls Digital Pathology 2.0 - a generational advancement in whole slide imaging technology. The company's flagship products are the Spectral family of scanners, which feature autonomous operation capable of handling most slide types without user intervention, including challenging specimens. Pramana's innovative approach separates slide handling mechanisms from scan heads, offering modular and scalable solutions that allow labs to customize their setup and quickly upgrade capacity as needs grow. The technology is built on a pioneering volumetric imaging method that replicates the fine-focus function of optical microscopes, backed by a portfolio of granted U.S. patents. Key differentiators include built-in inline quality assurance with fully autonomous rescanning, edge AI capability to execute multiple feature description algorithms in real time during scanning, and compatibility with diverse specimen types including tissue biopsies, cytology samples, bone marrow, microbiology slides, and wet mounts. The company addresses critical pain points in traditional digital pathology including high manual quality control burden, underutilized scanner capacity, and slow cloud-based image analysis. In August 2024, Pramana was acquired by Evident (formerly Olympus Scientific Solutions), expanding Evident's digital pathology portfolio. The company's solutions are designed for anatomic pathology, cytopathology, hematopathology, clinical pathology, and microbiology applications, serving healthcare organizations and research institutions globally.
Company description Pramana official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
On Premise deployment with recorded integration context.
Recorded integration context: IMS Vendors, Siemens Healthineers.
Company milestones
Acquired by Evident in August 2024; Health Canada authorization for SpectralM and SpectralHT Cubiq scanners in July 2024; Moffitt Cancer Center deployment in October 2024; Siemens Healthineers collaboration at Klinikum Ludwigshafen in September 2024
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Autonomous whole slide imaging system with inline quality assurance
High-throughput autonomous whole slide imaging scanner with modular, scalable design
Modular digital pathology scanner for smaller slide volumes and specialized applications
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Pediatric research · Jul 27, 2026
Reduction of biofilm and pathogenic microorganisms using curcumin-mediated photodynamic inactivation to prolong food shelf-life.International journal of food microbiology · Dec 2, 2024
Impact of coating particles on liquid marble lifetime: reactor engineering approach to evaporation.Soft matter · Jul 24, 2024
Baseline serum Mac-2 binding protein glycosylation isomer as a predictor of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis.Annals of gastroenterology · Jan 1, 2022
Perspectives on the evolution of mobile (mHealth) technologies and application to rehabilitation.Physical therapy · Mar 1, 2015
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Reduces manual quality control burden
High-throughput scanning efficiency
Results instantly available upon scan completion
Expand digital pathology adoption to support clinical and research initiatives using high-throughput scanning technology
Advance digital pathology through collaboration combining AI imaging, diagnostics expertise, and clinical leadership with Siemens Healthineers partnership
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Pramana's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.